the global share of research and development investments, clinical trials and manufacturing output all waning. The study finds that a key driver of most new investments is the location and performance of existing research and development or manufacturing footprint.
But the study reveals trends all of us should heed. In 2002, the US spent $2 billion more than Europe on research and development . Today, that figure is $20 billion. Of the total R&D investments made in the US, Europe, China and Japan, only 31 per cent occurs in Europe. This has declined steadily from 41 per cent in 2001. China has grown its share from 1 per cent to 8 per cent.
ATMPs are the therapies of the future, with 804 next-generation biotherapeutics, including cell and gene therapies and mRNA technology, in a global pipeline of more than 8,000 new medicines. The US has half the world’s ATMP manufacturing facilities. Asia is fast becoming the most competitive region for attracting ATMP clinical trials , with Europe in decline .
The study finds that global research and development is expected to grow at a rate of 4.2 per cent annually to $233 billion in 2026. The problem is that it is moving out of the EU. While world-leading hubs such as Boston, San Francisco and the UK’s golden triangle get significant policy focus and strategic funding, European research funding is more uniform across countries. The countries with the highest EU research spend per population are not the centres of innovation. This is a weak strategy.
The bioscientists just work for the same money month after month. Poach them from US big pharma that makes trillions off of their work while letting people die who can't afford it. Ethically, the rest of the world should reserve the right to ignore patents on life-saving med tech